Wu J - Search Results

1

Pharmacogenomic potential in advanced cancer patients.

Nichols D, Arnold S, Weiss HL, Wu J, Durbin EB, Miller R, Kolesar J. Nichols D, et al. Among authors: wu j. Am J Health Syst Pharm. 2019 Mar 19;76(7):415-423. doi: 10.1093/ajhp/zxy079. Am J Health Syst Pharm. 2019. PMID: 31361818 Free PMC article.

2

Phase II trial design with growth modulation index as the primary endpoint.

Wu J, Chen L, Wei J, Weiss H, Miller RW, Villano JL. Wu J, et al. Pharm Stat. 2019 Mar;18(2):212-222. doi: 10.1002/pst.1916. Epub 2018 Nov 20. Pharm Stat. 2019. PMID: 30458583 Free PMC article.

3

S100A4 alters metabolism and promotes invasion of lung cancer cells by up-regulating mitochondrial complex I protein NDUFS2.

Liu L, Qi L, Knifley T, Piecoro DW, Rychahou P, Liu J, Mitov MI, Martin J, Wang C, Wu J, Weiss HL, Butterfield DA, Evers BM, O'Connor KL, Chen M. Liu L, et al. Among authors: wu j. J Biol Chem. 2019 May 3;294(18):7516-7527. doi: 10.1074/jbc.RA118.004365. Epub 2019 Mar 18. J Biol Chem. 2019. PMID: 30885944 Free PMC article.

4

Two-stage phase II survival trial design.

Wu J, Chen L, Wei J, Weiss H, Chauhan A. Wu J, et al. Pharm Stat. 2020 May;19(3):214-229. doi: 10.1002/pst.1983. Epub 2019 Nov 21. Pharm Stat. 2020. PMID: 31749311 Free PMC article.

5

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells.

Burgess BT, Anderson AM, McCorkle JR, Wu J, Ueland FR, Kolesar JM. Burgess BT, et al. Among authors: wu j. Diagnostics (Basel). 2020 Feb 22;10(2):121. doi: 10.3390/diagnostics10020121. Diagnostics (Basel). 2020. PMID: 32098452 Free PMC article.

6

Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry.

Jacob A, Wu J, Kolesar J, Durbin E, Mathew A, Arnold S, Chauhan A. Jacob A, et al. Among authors: wu j. Cancer Med. 2021 Mar;10(6):2054-2062. doi: 10.1002/cam4.3802. Epub 2021 Feb 22. Cancer Med. 2021. PMID: 33619913 Free PMC article.

7

Molecular Tumor Board-Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial.

Miller RW, Hutchcraft ML, Weiss HL, Wu J, Wang C, Liu J, Jayswal R, Buchanan M, Anderson A, Allison DB, El Khouli RH, Patel RA, Villano JL, Arnold SM, Kolesar JM. Miller RW, et al. Among authors: wu j. JCO Precis Oncol. 2022 Aug;6:e2100524. doi: 10.1200/PO.21.00524. JCO Precis Oncol. 2022. PMID: 36103643 Free PMC article. Clinical Trial.

8

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer.

Myint ZW, Kolesar JM, McCorkle JR, Wu J, Ellis CS, Otto DE, Wang P. Myint ZW, et al. Among authors: wu j. Med Sci Monit. 2022 Oct 14;28:e938091. doi: 10.12659/MSM.938091. Med Sci Monit. 2022. PMID: 36229939 Free PMC article.

9

Estimating the distribution of ratio of paired event times in phase II oncology trials.

Chen L, Burkard M, Wu J, Kolesar JM, Wang C. Chen L, et al. Among authors: wu j. Stat Med. 2023 Feb 10;42(3):388-406. doi: 10.1002/sim.9622. Epub 2022 Dec 27. Stat Med. 2023. PMID: 36575855

10

Adjuvant Treatment of Triple-Negative Metaplastic Breast Cancer With Weekly Paclitaxel and Platinum Chemotherapy: Retrospective Case Review From a Single Institution.

Harper NW, Hodges KB, Stewart RL, Wu J, Huang B, O'Connor KL, Romond EH. Harper NW, et al. Among authors: wu j. Clin Breast Cancer. 2019 Aug;19(4):e495-e500. doi: 10.1016/j.clbc.2019.05.009. Epub 2019 May 24. Clin Breast Cancer. 2019. PMID: 31208874 Free PMC article. Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

72,450 results

Search Page